News | November 14, 2024
AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
To set a new standard in oncology, offering highly targeted radiation therapy that improves treatment precision, and accelerates recovery for cancer patients
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Subscribe To Our Newsletter & Stay Updated
